Cargando…
(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
High expression levels of the tumor-associated antigen MUC1 have been correlated with tumor aggressiveness, poor response to therapy, and poor survival in several tumor types, including breast, pancreatic, and epithelial ovarian cancer. Herein, we report the synthesis, characterization, and in vivo...
Autores principales: | Fung, Kimberly, Vivier, Delphine, Keinänen, Outi, Sarbisheh, Elaheh Khozeimeh, Price, Eric W., Zeglis, Brian M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287814/ https://www.ncbi.nlm.nih.gov/pubmed/32429033 http://dx.doi.org/10.3390/molecules25102315 |
Ejemplares similares
-
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
por: Sharma, Sai Kiran, et al.
Publicado: (2022) -
Visualizing
Galectin-3 Binding Protein Expression
with ImmunoPET
por: Keinänen, Outi, et al.
Publicado: (2023) -
(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018) -
Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017) -
Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)